Harvest Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.26M Sell
9,854
-465
-5% -$158K 0.14% 106
2025
Q4
$4.1M Buy
10,319
+8,298
+411% +$3.67M 0.15% 106
2025
Q3
$920K Buy
2,021
+896
+80% +$365K 0.04% 200
2025
Q2
$366K Buy
+1,125
New +$311K 0.02% 275
2024
Q4
Sell
-162
Closed -$45K 729
2024
Q3
$45K Buy
+162
New +$42.2K ﹤0.01% 465
2024
Q1
Sell
-23
Closed -$4K 658
2023
Q4
$4K Hold
23
﹤0.01% 579
2023
Q3
$4K Hold
23
﹤0.01% 571
2023
Q2
$4K Sell
23
-95
-81% -$18.8K ﹤0.01% 602
2023
Q1
$24K Sell
118
-283
-71% -$59.5K 0.01% 558
2022
Q4
$95K Buy
+401
New +$85.5K 0.02% 342
2022
Q2
Sell
-342
Closed -$55K 712
2022
Q1
$55K Sell
342
-532
-61% -$81.1K 0.01% 414
2021
Q4
$148K Hold
874
0.03% 290
2021
Q3
$165K Buy
874
+783
+860% +$147K 0.04% 188
2021
Q2
$15K Hold
91
﹤0.01% 668
2021
Q1
$12K Buy
+91
New +$13.7K ﹤0.01% 735
2020
Q4
Sell
-928
Closed -$131K 578
2020
Q3
$131K Buy
928
+380
+69% +$54K 0.01% 229
2020
Q2
$81K Sell
548
-414
-43% -$55.8K 0.01% 265
2020
Q1
$104K Sell
962
-46
-5% -$5.31K 0.01% 197
2019
Q4
$119K Buy
+1,008
New +$100K 0.01% 160

Other funds holding ALNY

Harvest Fund Management's ALNY Position: Q1 2026 in Review

Harvest Fund Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.5% in Q1 2026, selling an estimated $158K and leaving 9,854 shares worth $3.26M. The position accounts for 0.14% of the portfolio, ranked #106.

Harvest Fund Management first reported a position in ALNY in Q4 2019 and has held it in 19 quarters since. The position peaked at $4.1M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Harvest Fund Management held 9,854 shares of Alnylam Pharmaceuticals worth $3.26M as of Q1 2026.
  • Harvest Fund Management sold 465 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $158K.
  • Alnylam Pharmaceuticals made up 0.14% of Harvest Fund Management's portfolio in Q1 2026, its #106 holding.
  • Harvest Fund Management first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 19 quarters since.
  • Harvest Fund Management's Alnylam Pharmaceuticals position peaked at $4.1M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Harvest Fund Management's 13F filing for Q1 2026, filed 14 May 2026.